13F filer · CIK 1389933
DAFNA Capital Management LLC
LOS ANGELES, CA · filing since Q2 2013 · last filing Aug 14, 2026
Reported value
$524.4M
+$84.8M vs prior
Positions
88
New / sold out
17 / 12
Added / reduced
17 / 26
Turnover
15.8%
buys $76.1M · sells $114.7M
Top-10 weight
56.2%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | ASCENDIS PHARMA A/S | +48,469 | – | +$12.9M |
| Added | DENALI THERAPEUTICS INC | +420,514 | +132.0% | +$10.8M |
| Added | NEKTAR THERAPEUTICS | +153,202 | +92.7% | +$10.7M |
| Added | INSULET CORP | +51,000 | +469.2% | +$7.8M |
| Added | EDGEWISE THERAPEUTICS INC | +114,583 | +102.1% | +$4.7M |
| New | KYMERA THERAPEUTICS INC | +27,000 | – | +$3.1M |
| New | ADLAI NORTYE LTD | +239,553 | – | +$2.8M |
| Added | SYNDAX PHARMACEUTICALS INC | +117,900 | +54.2% | +$2.6M |
| New | NERVGEN PHARMA CORP | +1,050,000 | – | +$2.2M |
| Added | ORTHOPEDIATRICS CORP | +93,471 | +97.7% | +$1.8M |
24 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | DAY ONE BIOPHARMACEUTICALS I | -978,463 | -100.0% | $-21.0M |
| Reduced | SPDR S&P BIOTECH ETF | -122,000 | -38.3% | $-19.3M |
| Reduced | BIOHAVEN LTD | -708,142 | -83.7% | $-10.5M |
| Reduced | MBX BIOSCIENCES INC | -163,656 | -93.3% | $-9.0M |
| Sold out | ASCENDIS PHARMA A/S | -4,000,000 | -100.0% | $-5.9M |
| Reduced | COMPASS PATHWAYS PLC | -406,930 | -16.8% | $-5.8M |
| Sold out | KALVISTA PHARMACEUTICALS INC | -267,402 | -100.0% | $-5.4M |
| Sold out | ASCENDIS PHARMA A/S | -23,177 | -100.0% | $-5.3M |
| Reduced | BICARA THERAPEUTICS INC | -136,778 | -32.4% | $-4.1M |
| Reduced | CYTOKINETICS INC | -45,499 | -20.9% | $-3.9M |
28 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | REVOLUTION MEDICINES INCCOM | 562,630 | $105.4M | 20.09% |
| 2 | SPDR S&P BIOTECH ETFETF | 196,505 | $31.1M | 5.93% |
| 3 | COMPASS PATHWAYS PLCSPONSORED ADS | 2,011,952 | $28.5M | 5.43% |
| 4 | STEREOTAXIS INCCOM NEW | 13,680,554 | $23.5M | 4.49% |
| 5 | NEKTAR THERAPEUTICSCOM NEW | 318,380 | $22.2M | 4.24% |
| 6 | DENALI THERAPEUTICS INCCOM | 739,014 | $19.0M | 3.62% |
| 7 | IDEAYA BIOSCIENCES INCCOM | 497,240 | $18.5M | 3.53% |
| 8 | ATRICURE INCCOM | 597,431 | $16.7M | 3.19% |
| 9 | XENON PHARMACEUTICALS INCCOM | 250,772 | $15.1M | 2.89% |
| 10 | CYTOKINETICS INCCOM NEW | 171,998 | $14.7M | 2.79% |
78 more rows. Subscribe for $29/month to see every row, download the data and use the API.